Skip to content

Author

R. Loomba

We have 7 of 222 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.

The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy for metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) without cirrhosis, a disease...

Maria Mironova, Vlad Ratziu, M. Rinella et al. · 0 citations
Open access Aug 2026

ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.

BACKGROUND Thyroid hormone receptor β (THR-β) agonists reduce atherogenic lipids, hepatic fat, and improve histology in metabolic dysfunction-associated steatohepatitis (MASH). The phase 2a HERALD study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of the selective and potent THR-β agonist ALG-...

R. Loomba, Stanley Wang, Dimple Desai et al. · 0 citations
Sep 2026

Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.

BACKGROUND & AIMS Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis. APPROACH AND RESULTS Adults with biopsy-pro...

Veeral H. Ajmera, Linus Schwantes-An, Luis Antonio Díaz et al. · 0 citations
Sep 2026

Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.

BACKGROUND AND AIMS The American Association for the Study of Liver Diseases (AASLD) recommends that a decline in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) can be used as a non-invasive endpoint for treatment response in metabolic dysfunction-associated steatohepatitis (MAS...

R. Loomba, Rui-Qiu Chen, You-Xin Wang et al. · 0 citations
Open access Sep 2026

Gut microbiome and metabolite profiles are associated with subsequent histologic MASH in a longitudinal mouse model

ABSTRACT Detecting metabolic dysfunction-associated steatohepatitis (MASH) before fibrosis develops remains a major challenge. We used a longitudinal streptozotocin/high-fat diet (STAM/HFD) mouse model to identify microbial and metabolic features that emerge before histological MASH onset. Integrative 16S rRNA and unta...

Stephany Flores Ramos, Kelly A. Fogelson, V. Muti et al. · 0 citations
Review Aug 2026

Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.

Key research priorities include refining epidemiological estimates, standardizing biomarker cut-offs, elucidating dynamic interactions between alcohol and CMRFs, validating non-invasive prognostic tools, and evaluating therapies that target both metabolic and alcohol-related injury.

L. Díaz, E. Pose, Mads Israelsen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.